Trials Sponsors Conditions Drugs Pricing

Conditions

Reactive Hypoglycemia

Keywords

Reactive hypoglycemiaSitagliptinGlucagon-Like Peptide 1IncretinsPrediabetes

Outcome Measures

Primary Outcomes (1)

Clinical improvement assessed by a validated questionnaire
2 weeks

Secondary Outcomes (1)

Glucose, insulin, GLP1, GIP
First and last evaluations

Study Arms (2)

Sitagliptin

EXPERIMENTAL

Drug: Sitagliptin phosphate

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

Sitagliptin phosphateDrug

Sitagliptin phosphate 100 mg per day per 2 weeks

Also known as: Januvia

Sitagliptin

PlaceboDrug

Placebo 1 tablet per day per 2 weeks

Placebo

Eligibility Criteria

Age18 Years - 45 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Clinical and biochemical diagnosis of prediabetic reactive hypoglycemia
Must be able to swallow tablet

Sponsors & Collaborators

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Otherlead
Merck Sharp & Dohme LLC
Industrycollaborator

Study Sites (1)

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Mexico City, Mexico City, 14000, Mexico

MeSH Terms

Conditions

HypoglycemiaPrediabetic State

Interventions

Sitagliptin Phosphate

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesDiabetes MellitusEndocrine System Diseases

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

Francisco J Gomez-Perez, MD
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
PRINCIPAL INVESTIGATOR

Enrollment

20 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER

Study Record Dates

First Submitted

February 18, 2009

First Posted

February 19, 2009

Study Start

December 2008

Date type not reported

This date has not been verified as actual or estimated.

Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Sitagliptin

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Sitagliptin

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations